Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
1.985
-0.015 (-0.75%)
May 15, 2026, 12:14 PM EDT - Market open

Protalix BioTherapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
4114.6819.7623.6317.1138.99
Short-Term Investments
10.0815.5915.0720.935.07-
Cash & Short-Term Investments
51.0830.2734.8344.5622.1838.99
Cash Growth
46.66%-13.08%-21.84%100.90%-43.11%1.14%
Accounts Receivable
2.948.842.915.274.593.44
Inventory
30.4725.7321.2419.0516.817.95
Other Current Assets
1.861.831.11.061.311.29
Total Current Assets
86.3666.6760.0869.9344.8861.67
Net Property, Plant & Equipment
12.9512.5810.0210.889.649.92
Other Long-Term Assets
3.033.093.323.621.272.08
Total Assets
102.3482.3573.4284.4355.7973.67
Accounts Payable
4.295.264.534.325.866.99
Accrued Expenses
21.6719.8819.5919.5512.2716.43
Current Portion of Long-Term Debt
---20.25--
Current Portion of Leases
1.431.381.51.411.121.21
Unearned Revenue
----13.188.55
Total Current Liabilities
27.3926.5225.6245.5332.4333.18
Long-Term Debt
----28.1927.89
Long-Term Leases
7.056.944.034.624.174.38
Other Long-Term Liabilities
0.670.660.560.711.6414.26
Total Long-Term Liabilities
7.727.64.595.343446.53
Total Liabilities
35.1134.1230.2150.8766.4379.7
Common Stock
-0.080.080.070.050.05
Additional Paid-in Capital
-433.15421.53415.05379.17368.85
Retained Earnings
--385-378.39-381.55-389.86-374.93
Shareholders' Equity
67.2348.2343.2133.57-10.64-6.04
Total Liabilities & Equity
102.3482.3573.4284.4355.7973.67
Total Debt
8.488.325.5326.2833.4733.47
Net Cash (Debt)
42.621.9529.318.28-11.295.52
Net Cash Growth
94.07%-25.09%60.31%---
Net Cash Per Share
0.530.280.360.22-0.230.13
Book Value
67.2348.2343.2133.57-10.64-6.04
Book Value Per Share
0.840.610.530.41-0.22-0.14
Tangible Book Value
67.2348.2343.2133.57-10.64-6.04
Tangible Book Value Per Share
0.840.610.530.41-0.22-0.14
Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q